Skip to main content

Broadwood Partners, L.P.'s Form 4 filing

Lineage Cell Therapeutics, Inc. (LCTX) · filed Mar 25, 2022

Accession no.
0000919574-22-002418
Filed
Mar 25, 2022, 5:56 PM ET
Trade date
Mar 23-25, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions. Open-market purchases total $1.32M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Broadwood Partners, L.P.CIK 0001278386Director, 10% Owner
Bradsher Neal CCIK 0001278388Director, 10% Owner
Broadwood Capital IncCIK 000127838710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 23, 2022Common SharesPPurchaseAcquired+260,106$1.37+$355,304.834,265,485Direct
Mar 23, 2022Common SharesPPurchaseAcquired0$0.00$034,265,485Indirect
Mar 24, 2022Common SharesPPurchaseAcquired+200,000$1.42+$284,34034,465,485Direct
Mar 24, 2022Common SharesPPurchaseAcquired0$0.00$034,465,485Indirect
Mar 25, 2022Common SharesPPurchaseAcquired+470,000$1.44+$678,02234,935,485Direct
Mar 25, 2022Common SharesPPurchaseAcquired0$0.00$034,935,485Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)